

## **CURRICULUM VITAE**

### **Enrico Derenzini, MD, PhD**

Born in Bologna, Italy, on March the 16<sup>th</sup> 1978

## **EDUCATION and EXPERIENCES**

July 1997: High school graduation at Liceo Classico “L. Galvani”, Bologna

October 2003: **MD Degree** in Medicine and Surgery with honours at University of Bologna

2001-2003 attends as border student the Oncology Department, S.Orsola Hospital, Bologna.  
Chief: Prof. G. Biasco

2003-2007 residency/**fellowship in Medical Oncology** at the Oncology Department, S.Orsola Hospital, Bologna  
Chief: Prof. G. Biasco

2007 degree with honours at the School of Specialization in Medical Oncology, University of Bologna  
Chief: Prof. G. Biasco

2008-2012 residency/**fellowship in Hematology** at the Hematology and Medical Oncology Institute “L. e A. Seràgnoli”, S. Orsola Hospital, Bologna  
Chief: Prof. M. Baccarani

2012 degree with honours at the School of Specialization in Hematology, University of Bologna  
Chief: Prof. P.L. Zinzani

2009-2011 **Post Doctoral Fellow** at the Lymphoma/Myeloma Department, University of Texas **MD Anderson Cancer Center**, Houston, Texas. Chief: Prof. Anas Younes.

May 2013- September 2015

**Research Fellow** at the Lymphoma Department, **Memorial Sloan Kettering Cancer**, New York. Chief: Prof. Anas Younes.

2015- **PhD** in Biomedical Sciences/Hematology  
University of Bologna  
Chief: Prof. Lucio Ildebrando Cocco

February 2016, Started as **attending physician** at European Institute of Oncology, Milan.

March 2017, “Abilitazione a Professore seconda fascia nel Settore Malattie del Sangue, Oncologia e Reumatologia, 06/D3”.

Since December 2019: **Coordinator of the Working Group Hematology** of the Alliance Against Cancer network.

March 2020, Started as **Assistant Professor (RTD-B)** in Hematology, Department of Health Sciences, **University of Milan**, Italy

March 2022, Started as **Associate Professor** in Hematology, Department of Health Sciences, **University of Milan**, Italy

March 2022, Started as **Director of the Oncohematology Division**, **European Institute of Oncology**, **Milan**, Italy.

*Abstract Reviewer/Chair at the 2022 EHA meeting (Vienna)*

*Abstract Reviewer/Chair at the 2013 ASH meeting (New Orleans, USA) and at the 2019 ASH meeting (San Diego, USA)*

*Abstract Reviewer, Congress Officer, Chair 2014 ESMO congress (Madrid, Spain)*

*Reviewer for international peer reviewed journals in the field of Hematology-Oncology, including Clinical Cancer Research, British Journal Haematology, European Journal of Haematology, Future Oncology, Clinical Lymphoma Myeloma and Leukemia, Leukemia and Lymphoma.*

*Associate Editor of European Journal of Hematology.*

*Associate Editor of Frontiers in Oncology.*

### **Bio sketch and main research focus**

- *Professor Enrico Derenzini is the Head of the Oncohematology Division at the European Institute of Oncology, Milan, Italy, and Associate Professor at the Department of Health Sciences, University of Milan. He is faculty at the European School of Molecular Medicine (SEMM). He is Coordinator of the Hematology Working Group of the Alliance against Cancer network.*
- *The main field of clinical and research activity is the development of novel therapies for difficult to treat hematologic malignancies such as aggressive lymphomas and acute myeloid leukemias. Several clinical trials exploiting novel treatments, including cell therapies, are currently active at the Oncohematology Division of the European Institute of Oncology.*
- *During his postdoctoral fellowships at MD Anderson Cancer Center (Houston, Tx) and Memorial Sloan Kettering Cancer Center (New York, NY), Prof. Derenzini focused his research activity on the preclinical development of novel*

*therapeutic strategies targeting tumor microenvironment in Hodgkin Lymphoma and the MYC oncogene in aggressive lymphomas.*

- *Prof. Derenzini's lab at the European Institute of Oncology Campus is currently focusing on the translational and preclinical development of novel therapies based on synthetic lethality in MYC-driven lymphoma and acute myeloid leukemia.*
- *A very important field of research interest and activity is currently represented by adoptive cell immunotherapies, and more precisely by NK cell-based treatment approaches in lymphoma and leukemia.*

### **Author of 90 publications in international peer reviewed journals**

**H index: 28 (Scopus July 2023)**

### **List of publications**

- 1- Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, **Derenzini E**, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Continuous venetoclax in treatment-naïve TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. *Am J Hematol.* 2023 Jun 29. doi: 10.1002/ajh.27009.
- 2- Carbonaro R, Accardo G, Mazzocconi L, Pileri S, **Derenzini E**, Veronesi P, Caldarella P, De Lorenzi F. BIA-ALCL in patients with genetic predisposition for breast cancer: our experience and a review of the literature. *Eur J Cancer Prev.* 2023;32(4):370-376.
- 3- Travaini LL, Botta F, **Derenzini E**, Lo Presti G, Ferrari ME, Airò Farulla LS, Radice T, Mazzara S, Tarella C, Pileri S, Raimondi S, Ceci F. [<sup>18</sup>F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma. *Hematol Oncol.* 2023 May 20. doi: 10.1002/hon.3171.
- 4- Mazzara S, Travaini L, Botta F, Granata C, Motta G, Melle F, Fiori S, Tabanelli V, Vanazzi A, Ramadan S, Radice T, Raimondi S, Lo Presti G, Ferrari ME, Jereczek-Fossa BA, Tarella C, Ceci F, Pileri S, **Derenzini E**. Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL. *Blood Adv.* 2023;7(4):630-643.

- 5- **Derenzini E**, Gueli A, Risso A, Bruna R, Gottardi D, Cignetti A, Pileri S, Avvedimento EV, Tarella C. Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients. *Hematol Oncol*. 2022 Dec 19. doi: 10.1002/hon.3118.
- 6- De Filippi R, Marcacci G, **Derenzini E**, Musso M, Donnarumma D, Morelli E, Patti C, Maraglino AME, Scalone R, Simeone L, Becchimanzi C, Mele S, Crisci S, Morabito F, Pinto A. Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study. *Cancers (Basel)*. 2022;14(23):5846.
- 7- Merli M, Ferrarini I, Merli F, Busca A, Mina R, Falini B, Bruna R, Cairoli R, Marchetti M, Romano A, Cavo M, Arcaini L, Trentin L, Cattaneo C, **Derenzini E**, Fracchiolla NS, Marchesi F, Scattolin A, Billio A, Bocchia M, Massaia M, Gambacorti-Passerini C, Mauro FR, Gentile M, Mohamed S, Della Porta MG, Coviello E, Cilloni D, Visani G, Federici AB, Tisi MC, Cudillo L, Galimberti S, Gherlinzoni F, Pagano L, Guidetti A, Bertù L, Corradini P, Passamonti F, Visco C. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. *Hematol Oncol*. 2023;41(1):128-138.
- 8- Rodríguez M, Alonso-Alonso R, Fernández-Miranda I, Mondéjar R, Cereceda L, Tráscasa Á, Antonio-Da Conceição A, Borregón J, Gato L, Tomás-Roca L, Bárcena C, Iglesias B, Climent F, González-Barca E, Camacho FI, Mayordomo É, Olmedilla G, Gómez-Prieto P, Castro Y, Serrano-López J, Sánchez-García J, Montes-Moreno S, García-Cosío M, Martín-Acosta P, García JF, Planelles M, Quero C, Provencio M, Mahillo-Fernández I, Rodríguez-Pinilla SM, **Derenzini E**, Pileri S, Sánchez-Beato M, Córdoba R, Piris MA. An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy. *EJHaem*. 2022;3(3):722-733.
- 9- Mussetti A, **Derenzini E**, Clementine S, Sureda A. Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era. *Front Immunol*. 2022;13:1002615.
- 10- Vegliante MC, Mazzara S, Zaccaria GM, De Summa S, Esposito F, Melle F, Motta G, Sapienza MR, Opinto G, Volpe G, Bucci A, Gargano G, Enjuanes A, Tabanelli V, Fiori S, Minoia C, Clemente F, Negri A, Gulino A, Morello G, Scattone A, Zito AF, Tommasi S, Agostinelli C, Vitolo U, Chiappella A, Barbui AM, **Derenzini E**, Zinzani PL, Casadei B, Rivas-Delgado A, López-Guillermo A, Campo E, Moschetta A, Guarini A, Pileri SA, Ciavarella S. NR1H3 (LXR $\alpha$ ) is associated with pro-inflammatory

macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma. *Hematol Oncol.* 2022;40(5):864-875.

- 11- Tabanelli V, Melle F, Motta G, Mazzara S, Fabbri M, Agostinelli C, Calleri A, Del Corvo M, Fiori S, Lorenzini D, Cesano A, Chiappella A, Vitolo U, **Derenzini E**, Griffin GK, Rodig SJ, Vanazzi A, Sabattini E, Tarella C, Sapienza MR, Pileri SA. The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade. *Blood Adv.* 2022;6(15):4634-4644.
- 12- Calabretta E, Guidetti A, Ricci F, Di Trani M, Monfrini C, Magagnoli M, Bramanti S, Maspero D, Morello L, Merli M, Di Rocco A, Graudenzi A, **Derenzini E**, Antoniotti M, Rossi D, Corradini P, Santoro A, Carlo-Stella C. Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. *Br J Haematol.* 2022;198(1):82-92.
- 13- Bonfiglio F, Bruscazzin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Buehler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, **Derenzini E**, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfò L, Stathis A, Stüssi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabani H, Calcinotto A, Bertoni F, Bhagat G, Campo E, De Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and phenotypic attributes of splenic marginal zone lymphoma. *Blood.* 2022 Feb 3;139(5):732-747.
- 14- Pileri SA, Tabanelli V, Fiori S, Calleri A, Melle F, Motta G, Lorenzini D, Tarella C, **Derenzini E**. Peripheral T-Cell Lymphoma, Not Otherwise Specified: Clinical Manifestations, Diagnosis, and Future Treatment. *Cancers (Basel).* 2021 Sep 9;13(18):4535.
- 15- Davids MS, O'Connor OA, Jurczak W, Samaniego F, Fenske TS, Zinzani PL, Patel MR, Ghosh N, Cheson BD, **Derenzini E**, Brander DM, Reeves JA, Knopinska-Posluszny W, Allan JN, Phillips T, Caimi PF, Lech-Maranda E, Burke JM, Agajanian

- R, Pettengell R, Leslie LA, Cheah CY, Fonseca G, Essell JH, Chavez JC, Pagel JM, Sharman JP, Hsu Y, Miskin HP, Sportelli P, Weiss MS, Flinn IW. Integrated safety analysis of umbralisib, a dual PI3K $\delta$ /CK1 $\epsilon$  inhibitor, in relapsed/refractory lymphoid malignancies. *Blood Adv.* 2021 Sep 21;bloodadvances.2021005132. doi: 10.1182/bloodadvances.2021005132. Epub ahead of print.
- 16- Rossi A, Orecchioni S, Falvo P, Tabanelli V, Baiardi E, Agostinelli C, Melle F, Motta G, Calleri A, Fiori S, Corsini C, Casadei B, Mazzara S, Vitolo U, Bertolini F, Zinzani PL, Alcalay M, Pelicci PG, Pileri S, Tarella C, **Derenzini E**. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. *Leukemia.* 2021 Jul 24. doi: 10.1038/s41375-021-01347-6. Epub ahead of print.
- 17- Cuneo A, Rigolin GM, Coscia M, Quaresmini G, Scarfò L, Mauro FR, Motta M, Quaglia FM, Trentin L, Ferrario A, Laurenti L, Reda G, Ferrari A, Pietrasanta D, Sportoletti P, Re F, De Paoli L, Foglietta M, Giordano A, Marchetti M, Farina L, Del Poeta G, Varettoni M, Chiurazzi F, Marasca R, Malerba L, Ibatici A, Tisi MC, Stefoni V, Leone M, Baratè C, Olivieri J, Murru R, Gentile M, Sanna A, Gozzetti A, Gattei V, Gottardi D, **Derenzini E**, Levato L, Orsucci L, Penna G, Chiarenza A, Foà R. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. *Hematol Oncol.* 2021 Jul 13;10.1002/hon.2899. doi: 10.1002/hon.2899. Epub ahead of print.
- 18- **Derenzini E**, Tabanelli V, Sammassimo S, Mazzara S, Motta G, Melle F, Vanazzi A, Calleri A, Fiori S, Finazzi MC, Barbanti MC, Ramadan S, Gandini S, Pastano R, Rambaldi A, Pileri S, Tarella C. Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma. *Bone Marrow Transplant.* 2021 May 7. doi: 10.1038/s41409-021-01320-y. Epub ahead of print.
- 19- Pileri SA, Mazzara S, **Derenzini E**. Plasmablastic lymphoma: one or more tumours? *Haematologica.* 2021 May 6. doi: 10.3324/haematol.2021.278841. Epub ahead of print.
- 20- Pileri SA, Tripodo C, Melle F, Motta G, Tabanelli V, Fiori S, Vegliante MC, Mazzara S, Ciavarella S, **Derenzini E**. Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas. *Cells.* 2021 Mar 18;10(3):675. doi: 10.3390/cells10030675.
- 21- Fowler NH, Samaniego F, Jurczak W, Ghosh N, **Derenzini E**, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS,

- Zinzani PL. Umbralisib, a Dual PI3K $\delta$ /CK1 $\epsilon$  Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. *J Clin Oncol*. 2021 May 20;39(15):1609-1618.
- 22- **Derenzini E**, Mazzara S, Melle F, Motta G, Fabbri M, Bruna R, Agostinelli C, Cesano A, Corsini CA, Chen N, Righi S, Sabattini E, Chiappella A, Calleri A, Fiori S, Tabanelli V, Cabras A, Pruneri G, Vitolo U, Gianni AM, Rambaldi A, Corradini P, Zinzani PL, Tarella C, Pileri S. A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma. *Haematologica*. 2020 Aug 13. doi: 10.3324/haematol.2019.236455. Epub ahead of print.
- 23- Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N, Ladetto M, Gambacorti Passerini C, Salvini M, Marchetti M, Lemoli R, Molteni A, Busca A, Cuneo A, Romano A, Giuliani N, Galimberti S, Corso A, Morotti A, Falini B, Billio A, Gherlinzoni F, Visani G, Tisi MC, Tafuri A, Tosi P, Lanza F, Massaia M, Turrini M, Ferrara F, Gurrieri C, Vallisa D, Martelli M, **Derenzini E**, Guarini A, Conconi A, Cuccaro A, Cudillo L, Russo D, Ciambelli F, Scattolin AM, Luppi M, Selleri C, Ortu La Barbera E, Ferrandina C, Di Renzo N, Olivieri A, Bocchia M, Gentile M, Marchesi F, Musto P, Federici AB, Candoni A, Venditti A, Fava C, Pinto A, Galienucci P, Rigacci L, Armiento D, Pane F, Oberti M, Zappasodi P, Visco C, Franchi M, Grossi PA, Bertù L, Corrao G, Pagano L, Corradini P; ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Haematol*. 2020 Oct;7(10):e737-e745.
- 24- Sapienza MR\*, Pileri A\*, **Derenzini E\***, Melle F, Motta G, Fiori S, Calleri A, Pimpinelli N, Tabanelli V, Pileri S. Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. *Cancers (Basel)*. 2019 Apr 28;11(5). pii: E595. \* Equal contribution.
- 25- **Derenzini E**, Risso A, Ruella M, Spatola T, Milone G, Pioltelli P, Iori AP, Santarone S, Bosi A, Rambaldi A, Bacigalupo AP, Arcese W, Tarella C. Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. *Biol Blood Marrow Transplant*. 2019;25(7):1387-1394.
- 26- Pileri SA, **Derenzini E**, Melle F, Motta G, Calleri A, Antoniotti P, Maltoni V, Spagnolo S, Fiori S, Tabanelli V, Fabbri M. Dissecting diffuse large B-cell lymphomas of the

- "not otherwise specified" type: the impact of molecular techniques. *F1000Res*. 2018 Dec 21;7. pii: F1000 Faculty Rev-1966. doi:10.12688/f1000research.16755.1.
- 27- Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iulii V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, **Derenzini E**, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue. *Ann Oncol*. 2018 Dec 1;29(12):2363-2370..
- 28- **Derenzini E**, Mondello P, Erazo T, Portelinha A, Liu Y, Scallion M, Asgari Z, Philip J, Hilden P, Valli D, Rossi A, Djaballah H, Ouerfelli O, de Stanchina E, Seshan VE, Hendrickson RC, Younes A. BET Inhibition-Induced GSK3 $\beta$  Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. *Cell Rep*. 2018;24(8):2155-2166.
- 29- **Derenzini E**, Agostinelli C, Rossi A, Rossi M, Scellato F, Melle F, Motta G, Fabbri M, Diop F, Kodipad AA, Chiappella A, Vitolo U, Gaidano G, Tarella C, Pileri S. Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. *Br J Haematol*. 2019 Apr;185(2):330-334.
- 30- **Derenzini E**, Rossi A, Treré D. Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why. *J Hematol Oncol*. 2018;11(1):75.
- 31- L'Abbate A, Iacobucci I, Lonoce A, Turchiano A, Ficarra E, Paciello G, Cattina F, Ferrari A, Imbrogno E, Agostinelli C, Zinzani P, Martinelli G, **Derenzini E**, Storlazzi CT. RALE051: a novel established cell line of sporadic Burkitt lymphoma. *Leuk Lymphoma*. 2018;59(5):1252-1255.
- 32- Mondello P, **Derenzini E**, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. *Oncotarget*. 2017;8(8):14017-14028.
- 33- Di Rorà AG, Iacobucci I, Imbrogno E, Papayannidis C, **Derenzini E**, Ferrari A, Guadagnuolo V, Robustelli V, Parisi S, Sartor C, Abbenante MC, Paolini S, Martinelli G. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. *Oncotarget*. 2016 7(33):53377-53391.



- 34- Shono Y, Tuckett AZ, Liou HC, Doubrovina E, **Derenzini E**, Ouk S, Tsai JJ, Smith OM, Levy ER, Kreines FM, Ziegler CG, Scallion MI, Doubrovin M, Heller G, Younes A, O'Reilly RJ, van den Brink MR, Zakrzewski JL. Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF- $\kappa$ B-Controlled Oxidative Stress Responses. *Cancer Res.* 2016 Jan 15;76(2):377-89.
- 35- **Derenzini E**, Iacobucci I, Agostinelli C, Imbrogno E, Storlazzi CT, L Abbate A, Casadei B, Ferrari A, Di Rora AG, Martinelli G, Pileri S, Zinzani PL. Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. *Exp Hematol Oncol.* 2015 Aug 27;4:24.
- 36- Iacobucci I, Di Rorà AG, Falzacappa MV, Agostinelli C, **Derenzini E**, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, Martinelli G. *J Hematol Oncol.* 2015 Nov 5;8(1):125.
- 37- **Derenzini E**, Stefoni V, Pellegrini C, Gandolfi L, Broccoli A, Casadei B, Quirini F, Argnani L, Tonialini L, Zinzani PL. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. *BMC Cancer.* 2015 Nov 9;15:879.
- 38- Trino S, Iacobucci I, Erriquez D, Laurenzana I, Luca L, Ferrari A, Rorà AG, Papayannidis C, **Derenzini E**, Simonetti G, Lonetti A, Venturi C, Cattina F, Ottaviani E, Abbenante MC, Russo D, Perini G, Musto P, Martinelli G. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. *Oncotarget.* 2016 Mar 15;7(11):12951-61
- 39- **Derenzini E**, Agostinelli C, Imbrogno E, Iacobucci I, Casadei B, Brighenti E, Righi S, Fuligni F, Ghelli Luserna Di Rorà A, Ferrari A, Martinelli G, Pileri S, Zinzani PL. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. *Oncotarget.* 2015 Mar 30;6(9):6553-69.
- 40- Mondello P, Pitini V, Arrigo C, **Derenzini E**, Mian M. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. *Anticancer Res.* 2014 Sep;34(9):5121-5.
- 41- Pellegrini C, Argnani L, Broccoli A, Stefoni V, **Derenzini E**, Gandolfi L, Casadei B, Maglie R, Pileri S, Zinzani PL. Prognostic value of interim positron emission

tomography in patients with peripheral T-cell lymphoma. *Oncologist*. 2014 Jul;19(7):746-50.

- 42- **Derenzini E**, Casadei B, Broccoli A, Gandolfi L, Pellegrini C, Zinzani PL. Sequential therapy with alternating short courses of r-chop (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and r-fm (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. *Br J Haematol*. 2014 Aug;166(4):625-8.
- 43- **Derenzini E**, Zinzani PL, Cheson BD. Bendamustine: role and evidence in lymphoma therapy, an overview. *Leuk Lymphoma*. 2014 Jul;55(7):1471-8.
- 44- **Derenzini E**, Stefoni V, Maglie R, Casadei B, Pellegrini C, Broccoli A, Stefani G, Fanti S, Motta MR, Narducci R, Argnani L, Zinzani PL. Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. *Biol Blood Marrow Transplant*. 2013 Dec;19(12):1695-701.
- 45- Zinzani PL, **Derenzini E**, Pellegrini C, Celli M, Broccoli A, Argnani L. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. *Br J Haematol*. 2013 Dec;163(5):681-3.
- 46- Brandi G, **Derenzini E**, Falcone A, Masi G, Loupakis F, Pietrabissa A, Pinna AD, Ercolani G, Pantaleo MA, Di Girolamo S, Grazi GL, de Rosa F, Biasco G. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. *Clin Colorectal Cancer*. 2013 Sep;12(3):188-94.
- 47- Gentile G, Broccoli A, Brunocilla E, Schiavina R, Borghesi M, Romagnoli D, Bianchi L, **Derenzini E**, Agostinelli C, Franceschelli A, Colombo F, Zinzani PL. An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. *Anticancer Res*. 2013 Jun;33(6):2639-42.
- 48- Broccoli A, **Derenzini E**, Pellegrini C, Narducci R, Stefani G, Casadei B, Argnani L, Zinzani PL. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. *Clin Lymphoma Myeloma Leuk*. 2013 Aug;13(4):493-5.
- 49- Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, Corradini P, Spina M, Brusamolino E, Gianni AM, Santoro A, Botto B, **Derenzini E**, Pellegrini C, Argnani L. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian

- experience and results of its use in daily clinical practice outside clinical trials. *Haematologica*. 2013 Aug;98(8):1232-6.
- 50- Zinzani PL, Pellegrini C, **Derenzini E**, Argnani L, Pileri S. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. *Hematol Oncol*. 2013 Apr 26. doi: 10.1002/hon.2049.
- 51- **Derenzini E**, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. *Expert Opin Investig Drugs*. 2013;22(6):775-85.
- 52- Pastorelli F, **Derenzini E**, Plasmati R, Pellegrini C, Broccoli A, Casadei B, Argnani L, Salvi F, Pileri S, Zinzani PL. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. *Leuk Lymphoma*. 2013 Oct;54(10):2318-21.
- 53- **Derenzini E**, Casadei B, Pellegrini C, Argnani L, Pileri S, Zinzani PL. Non-Hodgkin Lymphomas Presenting as Soft Tissue Masses: A Single Center Experience and Meta-analysis of the Published Series. *Clin Lymphoma Myeloma Leuk*. 2012 Dec 12. pii: S2152-2650(12)00253-4.
- 54- Zinzani PL, Pellegrini C, Gandolfi L, Casadei B, **Derenzini E**, Broccoli A, Quirini F, Argnani L, Pileri S, Celli M, Fanti S, Poletti V, Stefoni V, Baccarani M. Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. *Hematol Oncol*. 2013 Dec;31(4):183-8.
- 55- Broccoli A, Stanzani M, Bandini G, Bonifazi F, Stefoni V, Pellegrini C, **Derenzini E**, Gandolfi L, Quirini F, Argnani L, Tschon M, Casadei B, Baccarani M, Zinzani PL. Allograft in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients. *Leuk Lymphoma*. 2013 Aug;54(8):1791-3.
- 56- Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, **Derenzini E**, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. *Hematol Oncol*. 2013 Dec;31(4):179-82.
- 57- Lemoine M, **Derenzini E**, Buglio D, Medeiros LJ, Davis RE, Zhang J, Ji Y, Younes A. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. *Blood*. 2012 Apr 26;119(17):4017-25.
- 58- Zinzani PL, **Derenzini E**, Pellegrini C, Rigacci L, Fabbri A, Gandolfi L, Argnani L, Casadei B, Pulsoni A, Gobbi M, Perotti A, Zaccaria A, Voso MT, Cabras MG, De Renzo A. Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and

mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). *Ann Oncol.* 2012 Mar;23(3):805-7+

- 59- **Derenzini E**, Lemoine M, Buglio D, Katayama H, Ji Y, Davis RE, Sen S and Younes A. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin Lymphoma. *Blood Cancer Journal* 2011, 1(12): e46.
- 60- Brandi G, Biasco G, Mirarchi MG, Golfieri R, Di Paolo A, Borghi A, Fanello S, **Derenzini E**, Agostini V, Giampalma E, Cappelli A, Pini P, Costantini S, Danesi R, Bolondi L, Piscaglia F. A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. *Dig Liver Dis.* 2011; 43(12):1015-21.
- 61- Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, **Derenzini E**, Broccoli A, Argnani L, Pileri S, Baccarani M. Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial. *Clin Lymphoma Myeloma Leuk.* 2011 Dec;11(6):462-6.
- 62- Pellegrini C, Gandolfi L, Quirini F, Ruggieri P, Stefoni V, **Derenzini E**, Broccoli A, Argnani L, Pileri S, Mercuri M, Baccarani M, Zinzani PL. Primary Bone Lymphoma: Evaluation of Chemoimmunotherapy as Front-line Treatment in 21 Patients. *Clin Lymphoma Myeloma Leuk.* 2011;11(4):321-5.
- 63- Jóna A, Khaskhely N, Buglio D, Shafer JA, **Derenzini E**, Bollard CM, Medeiros LJ, Illés A, Ji Y, Younes A. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. *Exp Hematol.* 2011 Oct;39(10):1007-1017.e1.
- 64- Lopci E, Burnelli R, Guerra L, Cistaro A, Piccardo A, Zucchetta P, **Derenzini E**, Todesco A, Garaventa A, Schumacher F, Farruggia P, Buffardi S, Sala A, Casale F, Indolfi P, Biondi S, Pession A, Fanti S. Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. *Eur J Nucl Med Mol Imaging.* 2011 Sep;38(9):1620-7.
- 65- **Derenzini E**, Younes A. Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. *Genome Med.* 2011 Apr 28;3(4):26.
- 66- Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, **Derenzini E**, Rossi M, Pileri S, Fanti S, Baccarani M. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in

- untreated intermediate/high-risk follicular lymphoma. *Ann Oncol.* 2012 Feb;23(2):415-20.
- 67- Zinzani PL, Pellegrini C, Broccoli A, Stefoni V, Gandolfi L, Quirini F, Argnani L, Berti E, **Derenzini E**, Pileri S, Baccarani M. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. *Leuk Lymphoma.* 2011 Aug;52(8):1585-8.
- 68- Zinzani PL, Gandolfi L, Broccoli A, Argnani L, Fanti S, Pellegrini C, Stefoni V, **Derenzini E**, Quirini F, Baccarani M. Midtreatment (18) F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. *Cancer.* 2011 Mar 1;117(5):1010-8. doi: 10.1002/cncr.25579.
- 69- Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, Montini GC, **Derenzini E**, Broccoli A, Argnani L, Pileri S, Baccarani M. Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. *Clin Lymphoma Myeloma Leuk.* 2010 Aug 1;10(4):258-61.
- 70- Zinzani PL, Pellegrini C, Stefoni V, **Derenzini E**, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. *Cancer.* 2010 Oct 15;116(20):4788-92.
- 71- Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, Petti MC, Stefoni V, Broccoli A, Fanti S, Pellegrini C, Montini GC, Gandolfi L, **Derenzini E**, Argnani L, Fina M, Tucci A, Bottelli C, Pileri S, Baccarani M. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. *Clin Cancer Res.* 2010 Aug 1;16(15):3998-4004.
- 72- Lopci E, Santi I, **Derenzini E**, Fonti C, Savelli G, Bertagna F, Bellò M, Botto B, Huglo D, Morschhauser F, Zinzani P, Fanti S. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. *Ann Oncol.* 2010 Sep;21(9):1877-83.
- 73- Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, **Derenzini E**, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. *Ann Oncol.* 2010 Apr;21(4):860-3.
- 74- **Derenzini E**, Fina MP, Stefoni V, Pellegrini C, Venturini F, Broccoli A, Gandolfi L, Pileri S, Fanti S, Lopci E, Castellucci P, Agostinelli C, Baccarani M, Zinzani

- PL.MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. *Ann Oncol.* 2010 Jun;21(6):1173-8.
- 75- Papayannidis C, **Derenzini E**, Iacobucci I, Curti A, Paolini S, Cilloni D, Baccarani M, Martinelli G. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. *Am J Hematol.* 2009 Dec;84(12):849-50.
- 76- **Derenzini E**, Stefoni V, Pellegrini C, Fina MP, Broccoli A, Venturini F, Gandolfi L, Pileri SA, Martelli M, Petti MC, Perrotti A, De Renzo A, Zaja F, Baccarani M, Zinzani PL. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. *Leuk Lymphoma.* 2009 Nov;50(11):1824-9.
- 77- Stefoni V, Broccoli A, Pellegrini C, **Derenzini E**, Fina M, Zinzani PL. CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. *J Neurooncol.* 2009 Oct;95(1):135-9.
- 78- Palandri F\*, **Derenzini E\***, Ottaviani E, Polverelli N, Catani L, Salmi F, Sabattini E, Bacci F, Zinzani PL, Baccarani M, Vianelli N. Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. \* Equal contribution. *Leuk Lymphoma.* 2009 Mar;50(3):481-4.
- 79- Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, Marchi E, Fina M, Ambrosini V, Pellegrini C, Alinari L, **Derenzini E**, Montini G, Broccoli A, Bacci F, Pileri S, Baccarani M. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. *J Clin Oncol.* 2009 Apr 10;27(11):1781-7.
- 80- **Derenzini E**, Musuraca G, Fanti S, Stefoni V, Tani M, Alinari L, Venturini F, Gandolfi L, Baccarani M, Zinzani PL. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. *Cancer.* 2008 Nov 1;113(9):2496-503.
- 81- Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, **Derenzini E**, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). *Lancet Oncol.* 2008 Apr;9(4):352-8.

- 82- Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini C, Alinari L, **Derenzini E**, de Vivo A, Bacci F, Pileri S, Baccarani M. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. *Ann Oncol.* 2008 Apr;19(4):769-73.
- 83- **Derenzini E**, Paolini S, Martinelli G, Campidelli C, Grazi GL, Calabrese C, Zinzani PL, Baccarani M. Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. *Leuk Lymphoma.* 2008 Jan;49(1):159-62.
- 84- Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Vitolo U, Perrotti A, Fina M, **Derenzini E**, Baccarani M. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. *Cancer.* 2008 Feb 15;112(4):856-62.
- 85- Zinzani PL, Poletti V, Zompatori M, Tani M, Spaggiari L, Tomassetti S, Broccoli A, **Derenzini E**, Baccarani M. Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. *Clin Lymphoma Myeloma.* 2007 Nov;7(9):566-72.
- 86- Fina M, Tani M, Stefoni V, Musuraca G, Marchi E, Pellegrini C, Alinari L, **Derenzini E**, Bacci F, Pileri S, Baccarani M, Zinzani PL. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. *Leuk Lymphoma.* 2007 Nov;48(11):2167-71.
- 87- Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, **Derenzini E**, de Vivo A, Sabbatini E, Pileri S, Baccarani M. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. *J Clin Oncol.* 2007 Sep 20;25(27):4293-7.
- 88- Biasco G, **Derenzini E**, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, Brandi G. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. *Cancer Treat Rev.* 2006 May;32(3):214-28.
- 89- Biasco G, Di Battista M, **Derenzini E**. Slow evolution of liver metastasis from colon cancer. *Dig Liver Dis.* 2005 Aug;37(8):628-9.
- 90- **Derenzini E**, Di Battista M, Di Marco MC, Dell'Arte S, Astorino M, Bertolini S, Brandi G, Biasco G. [Treatment of colorectal cancer liver metastases]. *Minerva Med.* 2006 Feb;97(1):107-19.

